CN110179827A - The application of Odontogenic cysts mescenchymal stem cell - Google Patents
The application of Odontogenic cysts mescenchymal stem cell Download PDFInfo
- Publication number
- CN110179827A CN110179827A CN201910570573.0A CN201910570573A CN110179827A CN 110179827 A CN110179827 A CN 110179827A CN 201910570573 A CN201910570573 A CN 201910570573A CN 110179827 A CN110179827 A CN 110179827A
- Authority
- CN
- China
- Prior art keywords
- stem cell
- mescenchymal stem
- dental pulp
- application
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 68
- 206010063413 odontogenic cyst Diseases 0.000 title claims abstract description 21
- 210000003074 dental pulp Anatomy 0.000 claims abstract description 43
- 239000003814 drug Substances 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 18
- 208000023589 ischemic disease Diseases 0.000 claims abstract description 14
- 210000004204 blood vessel Anatomy 0.000 claims abstract description 10
- 238000002360 preparation method Methods 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 29
- 239000007788 liquid Substances 0.000 claims description 13
- 230000017531 blood circulation Effects 0.000 claims description 12
- 210000003141 lower extremity Anatomy 0.000 claims description 8
- 201000002818 limb ischemia Diseases 0.000 claims description 7
- 210000003716 mesoderm Anatomy 0.000 claims description 7
- 230000001737 promoting effect Effects 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 3
- 239000007924 injection Substances 0.000 claims description 3
- 238000002347 injection Methods 0.000 claims description 3
- 238000013507 mapping Methods 0.000 claims description 3
- 210000004357 third molar Anatomy 0.000 claims description 3
- 238000012937 correction Methods 0.000 claims description 2
- 210000004489 deciduous teeth Anatomy 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000003349 gelling agent Substances 0.000 claims description 2
- 230000007170 pathology Effects 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 12
- 206010061218 Inflammation Diseases 0.000 abstract description 6
- 230000004054 inflammatory process Effects 0.000 abstract description 6
- 230000033115 angiogenesis Effects 0.000 abstract description 5
- 230000000302 ischemic effect Effects 0.000 abstract description 5
- 230000001506 immunosuppresive effect Effects 0.000 abstract description 4
- 230000004083 survival effect Effects 0.000 abstract description 4
- 230000002401 inhibitory effect Effects 0.000 abstract description 3
- 230000003110 anti-inflammatory effect Effects 0.000 abstract description 2
- 230000008929 regeneration Effects 0.000 abstract description 2
- 238000011069 regeneration method Methods 0.000 abstract description 2
- 230000017423 tissue regeneration Effects 0.000 abstract 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 33
- 210000003954 umbilical cord Anatomy 0.000 description 30
- 210000003414 extremity Anatomy 0.000 description 14
- 241000700159 Rattus Species 0.000 description 13
- 210000001105 femoral artery Anatomy 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 8
- 210000004271 bone marrow stromal cell Anatomy 0.000 description 7
- 230000029087 digestion Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 5
- 108090000631 Trypsin Proteins 0.000 description 5
- 239000006285 cell suspension Substances 0.000 description 5
- 238000000684 flow cytometry Methods 0.000 description 5
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 239000012588 trypsin Substances 0.000 description 5
- 208000032064 Chronic Limb-Threatening Ischemia Diseases 0.000 description 4
- 208000005764 Peripheral Arterial Disease Diseases 0.000 description 4
- 206010034576 Peripheral ischaemia Diseases 0.000 description 4
- 102100040247 Tumor necrosis factor Human genes 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000004069 differentiation Effects 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 210000004013 groin Anatomy 0.000 description 4
- 210000003289 regulatory T cell Anatomy 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 206010002091 Anaesthesia Diseases 0.000 description 3
- 102100021866 Hepatocyte growth factor Human genes 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 3
- 241000256856 Vespidae Species 0.000 description 3
- 230000037005 anaesthesia Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 210000000629 knee joint Anatomy 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 230000002980 postoperative effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 description 2
- 102000029816 Collagenase Human genes 0.000 description 2
- 108060005980 Collagenase Proteins 0.000 description 2
- 102100037241 Endoglin Human genes 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 206010017577 Gait disturbance Diseases 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 description 2
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 2
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 2
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 2
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 2
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 2
- 102100022338 Integrin alpha-M Human genes 0.000 description 2
- 206010028851 Necrosis Diseases 0.000 description 2
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 2
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 description 2
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 210000000068 Th17 cell Anatomy 0.000 description 2
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 210000000577 adipose tissue Anatomy 0.000 description 2
- 238000002583 angiography Methods 0.000 description 2
- 210000000544 articulatio talocruralis Anatomy 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 239000012267 brine Substances 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 230000009668 clonal growth Effects 0.000 description 2
- 229960002424 collagenase Drugs 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 238000011010 flushing procedure Methods 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 208000037906 ischaemic injury Diseases 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- 238000002660 stem cell treatment Methods 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 200000000007 Arterial disease Diseases 0.000 description 1
- 208000000575 Arteriosclerosis Obliterans Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- 206010017711 Gangrene Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 201000004328 Pulpitis Diseases 0.000 description 1
- 206010037464 Pulpitis dental Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 206010043540 Thromboangiitis obliterans Diseases 0.000 description 1
- 201000006704 Ulcerative Colitis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 210000001789 adipocyte Anatomy 0.000 description 1
- 230000002293 adipogenic effect Effects 0.000 description 1
- RGCKGOZRHPZPFP-UHFFFAOYSA-N alizarin Chemical compound C1=CC=C2C(=O)C3=C(O)C(O)=CC=C3C(=O)C2=C1 RGCKGOZRHPZPFP-UHFFFAOYSA-N 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000001949 anaesthesia Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 238000010009 beating Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 231100000012 chronic liver injury Toxicity 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 208000007147 dental pulp necrosis Diseases 0.000 description 1
- 210000005258 dental pulp stem cell Anatomy 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 108010007093 dispase Proteins 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000011132 hemopoiesis Effects 0.000 description 1
- 210000005104 human peripheral blood lymphocyte Anatomy 0.000 description 1
- 210000003090 iliac artery Anatomy 0.000 description 1
- 210000003692 ilium Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000004072 osteoblast differentiation Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000011506 response to oxidative stress Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000012549 training Methods 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 210000003556 vascular endothelial cell Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Developmental Biology & Embryology (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a kind of application of Odontogenic cysts mescenchymal stem cell, specially application of the Odontogenic cysts mescenchymal stem cell in preparation treatment ischemic disease drug.Dental pulp mescenchymal stem cell has stronger immunosuppressive activity and anti-inflammatory activity, at the same can promote ishemic part angiogenesis and blood vessel bypass to establish effect most strong.And dental pulp mescenchymal stem cell can be by inhibiting the foundation of ischemic local inflammation reaction, the survival and the offshoot circulation that promote the mechanism such as blood vessel and regeneration to promote mescenchymal stem cell, and then achievees the purpose that damaged tissue repair.
Description
Technical field
The present invention relates to medicinal application fields, in particular to a kind of application of Odontogenic cysts mescenchymal stem cell.
Background technique
A kind of most commonly seen blood vessel of lower limb peripheral arterial disease (Peripheral Arterial Diseases, PAD)
One of surgical disease, disease incidence are high.According to statistics, PAD threatens the quality of life and life expectancy of global about 200,000,000 people.Periphery
Arteriopathy includes Buerger's disease, arteriosclerosis obliterans and diabetes etc..In diabetes, hypertension, high blood
Under the effect of the risk factors such as rouge disease, smoking, chronic atherosclerosis, about 1% -2% peripheral arterial patient can be proceeded to
Terminal stage, i.e. critical limb ischemia (Critical limb ischemia, CLI), pain (limping), tranquillization when causing to walk
Bitterly, ulcer even results in tissue necrosis.Reconstructing blood vessel, including classical bypass art and interventional therapy are current CLI treatments
Main means.However, some patientss are not suitable for hand because in poor condition of health, the inflow undesirable elements such as road and efferent tract difference influence
Art treatment.Therefore, it researches and develops significantly more efficient therapeutic agent or treatment means seems very necessary and urgently.
A large number of studies show that locally injecting or use genophore import growth factor, such as fibroblast growth factor
(Fibroblast Growth Factor, FGF), vascular endothelial growth factor (Vascular Endothelial Growth
Factor, VEGF) and hepatocyte growth factor (Hepatocyte Growth Factor, HGF) etc., it can be in animal model
Effectively facilitate angiogenesis.However, a large amount of clinical researches show that growth factor for treating can not continue to mitigate patient's rest pain and control
More ulcer.Stem cell has self-renewing and directed differentiation potential, has proven to the reparation that can promote Various Tissues damage, such as radiates
Property injury of lungs, chronic liver injury, ulcerative colitis etc..But it is not on the books on treatment ischemic disease.
Summary of the invention
The present invention provides a kind of Odontogenic cysts mescenchymal stem cells to treat ischemic disease medicinal application in preparation, it is intended to mention
For the new application of Odontogenic cysts mescenchymal stem cell, expand its use scope.
The present invention is implemented as follows:
A kind of Odontogenic cysts mescenchymal stem cell treats ischemic disease medicinal application in preparation.
The beneficial effects of the present invention are: dental pulp mescenchymal stem cell of the invention is promoting angiogenesis and blood vessel bypass to build
Stand, and promote limb activity functional rehabilitation etc. all has biggish advantage, can be used for critical limb ischemia treatment.
The clear dental pulp mescenchymal stem cell of the present invention is inhibiting Th1 type cell, Th17 type cell and TNF-α expression etc. convenient
With stronger activity, and dental pulp mescenchymal stem cell can significantly promote the amplification of Tregs.In short, dental pulp mescenchymal stem cell
There is stronger immunosuppressive activity and anti-inflammatory activity compared with umbilical cord mesenchymal stem cells.
The clear mescenchymal stem cell of the present invention has significant therapeutic effect to critical limb ischemia, and dental pulp mesenchyma is dry thin
Born of the same parents have optimal efficiency, are expected to the clinical application of extension dental pulp mescenchymal stem cell, promote the treatment level of critical extremity ischemia.
Detailed description of the invention
It, below will be to use required in embodiment in order to illustrate more clearly of the technical solution of embodiment of the present invention
Attached drawing be briefly described, it should be understood that the following drawings illustrates only certain embodiments of the present invention, therefore is not to be seen as
It is the restriction to range, it for those of ordinary skill in the art, without creative efforts, can be with root
Other relevant attached drawings are obtained according to these attached drawings.
Fig. 1 is the Flow cytometry result of 2 dental pulp mescenchymal stem cell phenotype of the embodiment of the present invention；
Fig. 2 is the Flow cytometry result of 2 mesenchymal stem cell phenotype of the embodiment of the present invention；
Fig. 3 is the Flow cytometry result of 2 umbilical cord mesenchymal stem cells phenotype of the embodiment of the present invention；
Fig. 4 is the Flow cytometry result of 2 fat mesenchymal stem cell phenotype of the embodiment of the present invention；
Fig. 5 is that 2 dental pulp mescenchymal stem cell skeletonization (left side) of the embodiment of the present invention breaks up and breaks up the detection of (right side) ability at rouge
As a result；
Fig. 6 is that 2 umbilical cord mesenchymal stem cells skeletonization (left side) of the embodiment of the present invention breaks up and breaks up the detection of (right side) ability at rouge
As a result；
Fig. 7 is 3 dental pulp of the embodiment of the present invention and umbilical cord mesenchymal stem cells to Th1/Th2/Th17 cell depression effect
Compare；
Fig. 8 is that 3 dental pulp of the embodiment of the present invention and umbilical cord mesenchymal stem cells promote Autoimmune disease (Tregs)
The comparison of effect；
Fig. 9 is 3 dental pulp of the embodiment of the present invention and umbilical cord mesenchymal stem cells human peripheral blood lymphocyte TNF α expression inhibiting
The comparison of effect；
Figure 10 is that 4 part separate sources MSCs muscle drug treatment femoral artery ligation of the embodiment of the present invention causes under rat severe
After limb ischemic, rat lower limb exercise ability appraisal result；
Figure 11 is that 4 part separate sources MSCs muscle drug treatment femoral artery ligation of the embodiment of the present invention causes under rat severe
After limb ischemic, angiography detects rat lower limb vascular new life result；
Figure 12 is that 4 part separate sources MSCs muscle drug treatment femoral artery ligation of the embodiment of the present invention causes under rat severe
After limb ischemic, Immunofluorescence test blood vessel endothelium mark CD31 expression of results.
Specific embodiment
It in order to make the object, technical scheme and advantages of the embodiment of the invention clearer, below will be in the embodiment of the present invention
Technical solution be clearly and completely described.The person that is not specified actual conditions in embodiment, according to normal conditions or manufacturer builds
The condition of view carries out.Reagents or instruments used without specified manufacturer is the conventional production that can be obtained by commercially available purchase
Product.
A kind of Odontogenic cysts mescenchymal stem cell, which is provided, to the embodiment of the present invention below treats ischemic disease drug in preparation
Using illustrating.
Specifically, the embodiment of the present invention provides a kind of Odontogenic cysts mescenchymal stem cell and treats ischemic disease drug in preparation
Using.
Inventors have found that the oxidative stress of ischemic injuries induction and inflammatory reaction etc., it is dry thin to considerably reduce mesenchyma
The survival rate of born of the same parents then reduces its effect.Inventor is further discovered that Odontogenic cysts mescenchymal stem cell is dry for dental pulp mesenchyma
It when cell, can more efficiently inhibit inflammation etc., promote the survival rate of dental pulp mescenchymal stem cell, then promote its treatment effect
Fruit.It uses dental pulp mescenchymal stem cell for specific mescenchymal stem cell, can be further ensured that Odontogenic cysts mescenchymal stem cell
There is better therapeutic effect for ischemic disease.
Further, dental pulp mescenchymal stem cell is from the adult wisdom tooth in the deciduous teeth that fall off, teenager's correction tooth and 18-35 years old
One of or it is a variety of.
Further, ischemic disease is ischemic disease of lower extremity, and ischemic disease is severe limb ischemia pathologies.
Further, the effective dose of Odontogenic cysts mescenchymal stem cell is 1x10 in drug6To 1.67x107A/milliliter.
The dosage form of drug includes any one in cell suspending liquid injection, gelling agent and spray.Using above-mentioned concentration
Drug can reduce side effects of pharmaceutical drugs, and guarantee the therapeutic effect of drug.
Further, inventor has found that Odontogenic cysts mescenchymal stem cell is improving the confession of operation side blood flow and improving operation side
There is significant effect in limb ischemia degree, then the embodiment of the present invention provides a kind of Odontogenic cysts mescenchymal stem cell and changes in preparation
Application in kind operation side supply of blood flow and the drug of improvement operation side limb ischemia degree.Wherein, improve operation side blood flow
Supply includes promoting the foundation of angiogenesis and new Doppler flow mapping.
It is specific to a kind of application progress of Odontogenic cysts mescenchymal stem cell provided by the invention below in conjunction with specific embodiment
Explanation.
The embodiment of the present invention uses dental pulp mescenchymal stem cell for experimental example, to fill between umbilical cord mesenchymal stem cells, marrow
Matter stem cell and fat mesenchymal stem cell are that comparative example is detected.
The separation and culture of 1 mescenchymal stem cell of embodiment
(1) dental pulp mescenchymal stem cell is separately cultured
Tooth is sterile under anaesthesia to pull out no saprodontia, without pulpitis and pulp necrosis after donor signs informed consent form
Third molar.The fresh tooth pulled out is immediately placed in the tooth collecting bottle equipped with 20ml sterile saline, for 24 hours interior separation
Cultivate dental pulp stem cell.Method particularly includes: corona Hou Qu pulp tissue is shredded, is shredded after physiological saline repeated flushing；It is placed in
In the physiological saline of collagenase type I containing 3mg/ml and 4mg/ml Dispase, 37 DEG C of water-baths digest 40min；Then, 70 μm are crossed
Cell sieve collects cell, and 1000rpm is centrifuged 10min, is resuspended with appropriate MSC serum free medium at single cell suspension, by cell
It is inoculated in 10cm culture dish, in 37 DEG C, 5%CO2Culture, changes the liquid once for 3-5 days.Cell is observed under inverted microscope daily
Upgrowth situation after 10-14 day, 0.25% trypsin digestion of the cell of Clonal growth is collected, obtains P0 between dental pulp
Mesenchymal stem cells.
(2) umbilical cord mesenchymal stem cells are separately cultured
After multipara agrees to and signs informed consent form, umbilical cord is stored in equipped with containing 300ml α-MEM culture medium
In 500ml sterile glass vials, stored in 4 DEG C, and be separately cultured umbilical cord stem cells in 24 hours after collection.Biohazard Safety Equipment takes
Out after umbilical cord, the segment cleaned repeatedly with sterile saline, and cut into 2cm or so, and umbilical vein and arteria umbilicalis are picked, take glue
Freeze the part Wharton ' s jelly of shape；Shredded into 5mm3Size tissue block successively puts tissue block with dropper in preparatory
In the 10cm culture dish of wetting, after a small amount of serum free medium is added, in 37 DEG C, 5%CO2Cultivate 48h；Continue to train after fluid infusion
It supports, changes the liquid once within every 3-4 days；Visible spindle shape cell climbs out of within 7-10 days；10~14 days, tissue block is removed, by Clonal growth
Cell collected with 0.25% trypsin digestion, obtain P0 for umbilical cord mesenchymal stem cells.
(3) mesenchymal stem cell is separately cultured
After donor agrees to and signs informed consent form, acquisition donor's myeloid tissue is placed in aseptic collection pipe.
Firstly, using Percoll partition method, separating bone marrow single nuclear cell；After brine, using MSC free serum culture
Base weight hangs mononuclearcell；By it according to 2.0 × 105/cm2Density be inoculated into 10cm culture dish, in 37 DEG C, 5%CO2Training
It supports；It changes liquid after 48h, removes non-attached cell, then change liquid every 48h, after clone to be formed, with 0.25% trypsin digestion
It collects, obtains P0 for umbilical cord mesenchymal stem cells.
(4) fat mesenchymal stem cell is separately cultured
After donor is agreed to and signs informed consent form, donor adipose tissue is acquired, is placed in equipped with 300ml α-MEM's
In 500ml culture bottle, 4 DEG C of preservations, and in interior separation for 24 hours.Specifically: adipose tissue is put into strainer, it is anti-through physiological saline
After multiple flushing, it is cut into 2mm3Size or so；Cross sieve and point to 50ml centrifuge tube, 100g is centrifuged 3min, collect upper-layer fat in
50ml centrifuge tube；Addition standard digestive juice 20ml (collagenase type I concentration 0.2%, trypsinase concentration 0.05%, the two 1:1),
37 DEG C of shaking bath 45min；3000rpm, centrifugation 10min collect cell；Cell suspension is mixed with erythrocyte cracked liquid 1:2,
1800rpm, 8min after gently blowing and beating abandon supernatant, the cell suspension of collection are filtered through 100 μM of cell sieves, 1800r/min centrifugation
8min obtains mononuclearcell；Culture medium is added, cell concentration is adjusted to 104A cell/ml, is inoculated in 10cm culture dish
(10ml) is placed in 37 DEG C of 5%CO2Incubator culture；After inoculation for 24 hours, it is seen that many short fusiform attached cells；It is changed after 48 hours
Liquid changes the liquid once for every 3 days later；7-10 days cells have been paved with bottle wall substantially and have formed fine and close single layer, are disappeared with 0.25% trypsase
Change and collect, obtains P0 for umbilical cord mesenchymal stem cells.
The immunophenotype of 2 mescenchymal stem cell of embodiment and the detection of multinomial differentiation potential
The P0 obtained is collected for mescenchymal stem cell (dental pulp, umbilical cord, marrow, fat) with 6000-8000 cell/cm2's
Density is passed on, and after cultivating 4d, is collected cell with 0.25% trypsin digestion, is continued to pass on.Be passaged to P5 generation, respectively into
Row immunophenotype and the detection of multinomial differentiation potential.It is specific as follows:
(1) immunophenotype detects
Mescenchymal stem cell after 0.25% trypsin digestion, CD73, CD90 for being marked using FITC or PE, CD105,
The antibody such as CD11b, CD19, CD34, CD45, HLA-DR and corresponding isotype control Ab mark cell, flow cytomery.
Testing result referring to figures 1-4, according to Fig. 1-Fig. 4 display it is found that separate sources mescenchymal stem cell (dental pulp, umbilical cord, marrow,
Fat) high expression mescenchymal stem cell specific antigen CD73, CD90 and CD105, do not express hematopoiesis and immunocyte surface
Indicate CD11b, CD19, CD34, CD45, hardly expression trnasplantion immunity repels relevant surface marker HLA-DR.These results
It is dry to successfully obtain dental pulp mescenchymal stem cell, umbilical cord mesenchymal stem cells, medulla mesenchyma by the method for embodiment 1 for prompt
Cell, fat mesenchymal stem cell.
(2) multi-lineage potential detects
Osteoblast Differentiation: by the P6 of separate sources for mescenchymal stem cell (dental pulp, umbilical cord, marrow, fat) respectively according to 1 ×
104Cells/well is inoculated with 24 well culture plates, is placed in 37 DEG C, 5%CO2, humidity 95% incubator in cultivate.After 24 hours, it is added
Osteogenic induction liquid changes liquid in every 4 days.3 Zhou Houyong Alizarin red stainings are induced to be identified.
Break up at rouge: by the P6 of separate sources for mescenchymal stem cell (dental pulp, umbilical cord, marrow, fat) respectively according to 1.5
×104Cells/well is inoculated with 24 well culture plates, is placed in 37 DEG C, 5%CO2, humidity 95% incubator in cultivate.After 24 hours, add
Enter adipogenic induction liquid, changes liquid within every 4 days.2 Zhou Houyong oil red O (Oil Red O) dyeing is induced to be identified.
Testing result shows to separate dental pulp mescenchymal stem cell, the umbilical cord mesenchyma of acquisition referring to Fig. 5-Fig. 6, Fig. 5-Fig. 6
Stem cell, mesenchymal stem cell and fat mesenchymal stem cell all have skeletonization and at rouge differentiation potentials.
3 dental pulp of embodiment and umbilical cord mesenchymal stem cells immunosuppressive activity compare,
Respectively with P6 for dental pulp mescenchymal stem cell or umbilical cord mesenchymal stem cells, with human peripheral blood single nucleus cell with 1:
Be incubated for jointly after the number of cells ratio mixing of 1,1:5,1:10 (incubation conditions are as follows: 37 DEG C, 5%CO2, saturated humidity incubator
In), 48h after incubation, using the different subtype of Flow cytometry T lymphocyte, such as Th1, Th2, Th17 and Tregs,
The expression and secretion of TNF-α are detected simultaneously.
Testing result is according to table 1 and Fig. 7 it is found that single with peripheral blood in mescenchymal stem cell referring to table 1 and Fig. 7-Fig. 9
Under conditions of nucleus is incubated for jointly with 1:5 ratio, suppression of the dental pulp mescenchymal stem cell to Th1 type and Th17 type T lymphocyte
Rate processed is 52.57 ± 8% and 61.37 ± 3.53%, is significantly higher than umbilical cord mesenchymal stem cells；Two pairs of Th2 type cells are 44.53
± 13.52%, lower than the 67.98 ± 12.25% of umbilical cord mesenchymal stem cells.According to table 1 and Fig. 8 it is found that promotion to Tregs
Rate is difference 71.6 ± 23.4, is significantly higher than umbilical cord mesenchymal stem cells.It is according to table 1 and Fig. 9 it is found that dry thin with umbilical cord mesenchyma
Cell phase ratio, dental pulp mescenchymal stem cell have stronger inhibition efficiency to the expression of lymphocyte TNF-α.In conclusion between dental pulp
Mesenchymal stem cells have stronger immune and inflammation depression effect, illustrate that dental pulp mescenchymal stem cell can be induced in ischemic injuries
Oxidative stress and inflammatory reaction etc., promote the survival rate of dental pulp mescenchymal stem cell, then promote its therapeutic effect.
1 dental pulp of table and umbilical cord mesenchymal stem cells immunosuppressive effect compare
The therapeutic evaluation of 4 tooth mesenchymal stem cells for treatment femoral artery ligation rat critical extremity ischemia of embodiment
Wistar rat 60, half male and half female, weight (200-280) g is randomly divided into 6 groups by weight, every group 10, divides
It Wei not sham-operation group, model control group, BMMSC (marrow), ADMSC (fat), DPMSC (dental pulp), 6 groups of UCMSC (umbilical cord).
(1) firstly, carrying out the preparation that femoral artery ligation causes rat lower limb ischemia model, specifically: rats by intraperitoneal injection
After the anesthesia of 40mg/kg yellow Jackets, dorsal position is fixed, and preserved skin, left lower quadrant does longitudinal opening, ligatures left common iliac artery and ilium is dynamic
All branches of arteries and veins；Left side groin longitudinal opening, separation ligature nearly two branch of groin femoral artery.Successively close notch, seam
Close muscle layer and skin.Sham-operation group only separates but does not ligature blood vessel.
(2) it is treated and (is filled between dental pulp mescenchymal stem cell, umbilical cord mesenchymal stem cells, marrow in operation same day administration
Matter stem cell, the treatment method of fat mesenchymal stem cell are identical, and difference, which is only that, is replaced cell), specifically: digestion
The 6th generation mescenchymal stem cell is collected, 1800rpm is centrifuged 8min and collects cell, and it is then primary with brine, according to 1.7
×107Cell/ml, which is resuspended, obtains stem cell suspension, and reagent group single intramuscular injection stem cell suspension, dosage is respectively 5 × 106
Cell/0.3ml/5 point/only；Model control group single intramuscular injection solvent 0.3ml/5 point/only.
(3) surrounding is observed, metrics evaluation is carried out:
1. limb scores: (0=sole/toe flexion is to resist tail for 1w, 2w, 3w, 4w progress limb scores after administration
Mild traction；1=plantar flexed, toe are not bent；The vola 2=and toe are not bent；3=does not use hind leg).And it calculates
The AUC of (1-4) w scoring, compares the difference of each group score value and model control group；
2. Doppler measures blood flow: 1w, 2w, 3w, 4w after administration, 40mg/kg yellow Jackets anesthetized rat is injected intraperitoneally,
Left lower extremity depilation preserved skin, the nearly groin femoral artery blood flow velocity in measurement operation side, and the AUC of (1-4) w blood flow velocity is calculated, than
The difference of more each administration group blood flow velocity and model control group；
3. angiography: 4w after administration, dorsal position is fixed after the anesthesia of rats by intraperitoneal injection 40mg/kg yellow Jackets, from
Groin makees longitudinal cut to knee joint, separates femoral artery, ligatures proximal part, and distal end does arterial cannulation, injects contrast agent iodine
General sieve amine injection (0.6-0.8) ml, continuously takes the photograph piece with X-ray machine immediately after injecting.Observe each administration group new vessels situation；
4. Histological evaluation: after X-ray takes the photograph piece, taking the left limb knee joint of rat to ankle-joint section muscle, be put into 11% formal
It is fixed in woods solution, for detecting capillary density, muscular death and inflammatory reaction situation.
4) experimental result:
As shown in table 2 and Figure 10, after ligation operation, there is limping, cyanosis, extremity gangrene in various degree in animal pattern, and
Postoperative (1-4) w, limb scores maintain 2 or more, show moulding success, and model is more stable.Between dental pulp, umbilical cord, fat, marrow
After mesenchymal stem cells treatment, limb scores have different degrees of reduction, comprehensive limb scores situation, and DPMSC can significantly mitigate operation
Side limb ischemia degree, AUC have statistical difference compared with model control group.
2 test drug MSC of table to rat art side limb scores influence (score value,N=8-10)
Note: compared with sham-operation group,***P<0.001；Compared with model control group,▲P<0.05.N: number of animals.
As shown in table 3, postoperative 1-4 weeks, animal pattern art side femoral artery blood flow velocity was substantially reduced, with sham-operation group ratio
Compared with having a statistical difference, mescenchymal stem cell treatment then has the tendency that improving art side supply of blood flow.As shown in figure 11, postoperative 4w,
Rat art side knee joint develops to ankle-joint section blood vessel, and model control group significantly reduces, and people's dental pulp, bone marrow mesenchymal stem cells are controlled
Visible vessels are newborn after treatment, and new Doppler flow mapping is established, especially best with the therapeutic effect of dental pulp mescenchymal stem cell.Such as Figure 12
Shown, histopathology is the results show that mescenchymal stem cell treatment can improve the institutional framework of ischemic part, reduction tissue
Necrosis promotes regeneration, wherein the proliferation of visible a large amount of vascular endothelial cells, it is new to show that mescenchymal stem cell can promote blood vessel
It is raw, the comparative studies of four kinds of cells is shown, dental pulp mescenchymal stem cell has significant optimal efficiency in promoting angiogenesis.
3 test drug MSC of table to femoral artery blood flow velocity influence (N=8-10)
Note: compared with sham-operation group, P < 0.001 * * *.
In short, dental pulp mescenchymal stem cell has optimal efficiency in critical extremity ischemia disease treatment.
The foregoing is merely the preferred embodiment of the present invention, are not intended to restrict the invention, for this field
For technical staff, the invention may be variously modified and varied.All within the spirits and principles of the present invention, made any
Modification, equivalent replacement, improvement etc., should all be included in the protection scope of the present invention.
Claims (10)
1. a kind of Odontogenic cysts mescenchymal stem cell treats ischemic disease medicinal application in preparation.
2. application according to claim 1, which is characterized in that Odontogenic cysts mescenchymal stem cell is that dental pulp mesenchyma is dry thin
Born of the same parents.
3. application according to claim 2, which is characterized in that the dental pulp mescenchymal stem cell from the deciduous teeth that fall off,
One of teenager's correction tooth and 18-35 years old adult wisdom tooth are a variety of.
4. application according to claim 1, which is characterized in that the ischemic disease is ischemic disease of lower extremity.
5. application according to claim 1, which is characterized in that the ischemic disease is severe limb ischemia pathologies.
6. application according to claim 1, which is characterized in that the effective agent of Odontogenic cysts mescenchymal stem cell in the drug
Amount is 1x106To 1.67x107A/milliliter.
7. application according to claim 6, which is characterized in that the dosage form of the drug include cell suspending liquid injection,
Any one in gelling agent and spray.
8. a kind of application of Odontogenic cysts mescenchymal stem cell in the drug that preparation improves operation side supply of blood flow.
9. application according to claim 8, which is characterized in that the improvement operation side supply of blood flow includes promoting blood vessel new
The foundation of raw and new Doppler flow mapping.
10. a kind of application of Odontogenic cysts mescenchymal stem cell in the drug that preparation improves operation side limb ischemia degree.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910570573.0A CN110179827A (en) | 2019-06-27 | 2019-06-27 | The application of Odontogenic cysts mescenchymal stem cell |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910570573.0A CN110179827A (en) | 2019-06-27 | 2019-06-27 | The application of Odontogenic cysts mescenchymal stem cell |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN110179827A true CN110179827A (en) | 2019-08-30 |
Family
ID=67723945
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910570573.0A Pending CN110179827A (en) | 2019-06-27 | 2019-06-27 | The application of Odontogenic cysts mescenchymal stem cell |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN110179827A (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110070209A1 (en) * | 2000-04-06 | 2011-03-24 | Franco Wayne P | Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs |
| CN103387959A (en) * | 2012-10-19 | 2013-11-13 | 夏佑红 | Stem cell from deciduous teeth, and preparation method and application thereof |
| CN107828722A (en) * | 2016-11-04 | 2018-03-23 | 北京泰盛生物科技有限公司 | Specific expressed PD 1 stem cell, its be identified and isolated from method and purposes |
| CN107846903A (en) * | 2015-05-28 | 2018-03-27 | 细胞结构公司 | The stem cell in placenta source and its for recovering regeneration engine, correcting protein group defect and extending the purposes in aging individuals life-span |
| CN108324926A (en) * | 2018-03-23 | 2018-07-27 | 高志涛 | The composition and application thereof of stem cell extract and antibacterial peptide |
| CN109219441A (en) * | 2016-03-09 | 2019-01-15 | 阿威他国际有限公司 | Express the purposes of dental pulp stem cell of mesenchyma and neuronal marker and combinations thereof treatment neurological disease |
| CN109432128A (en) * | 2018-12-07 | 2019-03-08 | 卡替（上海）生物技术股份有限公司 | Application of the dental pulp mescenchymal stem cell in curing psoriasis |
| CN109966317A (en) * | 2017-12-01 | 2019-07-05 | 凯薾国际生医有限公司 | Neuroprotective composition, preparation method and its medical usage |
-
2019
- 2019-06-27 CN CN201910570573.0A patent/CN110179827A/en active Pending
Patent Citations (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110070209A1 (en) * | 2000-04-06 | 2011-03-24 | Franco Wayne P | Combination growth factor therapy and cell therapy for treatment of acute and chronic diseases of the organs |
| CN103387959A (en) * | 2012-10-19 | 2013-11-13 | 夏佑红 | Stem cell from deciduous teeth, and preparation method and application thereof |
| CN107846903A (en) * | 2015-05-28 | 2018-03-27 | 细胞结构公司 | The stem cell in placenta source and its for recovering regeneration engine, correcting protein group defect and extending the purposes in aging individuals life-span |
| CN109219441A (en) * | 2016-03-09 | 2019-01-15 | 阿威他国际有限公司 | Express the purposes of dental pulp stem cell of mesenchyma and neuronal marker and combinations thereof treatment neurological disease |
| CN109312303A (en) * | 2016-03-09 | 2019-02-05 | 阿威他国际有限公司 | Express stem cell, its composition and preparation method thereof of mesenchyma and neuronal marker |
| CN107828722A (en) * | 2016-11-04 | 2018-03-23 | 北京泰盛生物科技有限公司 | Specific expressed PD 1 stem cell, its be identified and isolated from method and purposes |
| CN109966317A (en) * | 2017-12-01 | 2019-07-05 | 凯薾国际生医有限公司 | Neuroprotective composition, preparation method and its medical usage |
| CN108324926A (en) * | 2018-03-23 | 2018-07-27 | 高志涛 | The composition and application thereof of stem cell extract and antibacterial peptide |
| CN109432128A (en) * | 2018-12-07 | 2019-03-08 | 卡替（上海）生物技术股份有限公司 | Application of the dental pulp mescenchymal stem cell in curing psoriasis |
Non-Patent Citations (1)
| Title |
|---|
| 庄雪莹等: "牙源性干细胞促进血管生成研究进展", 《中国实用口腔科杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6286689B2 (en) | Cosmetic or skin regeneration promoter using non-human stem cell culture supernatant as raw material, and protein iontophoresis method | |
| CN103893211A (en) | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation | |
| ES2550456T3 (en) | Use of a composition containing mesenchymal stem cells derived from human umbilical cord blood to induce differentiation and proliferation of neural precursor cells or neural stem cells to neural cells | |
| US8277795B2 (en) | Methods and compositions for treating motor neuron diseases comprising mesenchymal stem cells | |
| Al Demour et al. | Safety and efficacy of 2 intracavernous injections of allogeneic Wharton’s jelly-derived mesenchymal stem cells in diabetic patients with erectile dysfunction: phase 1/2 clinical trial | |
| CN104707140A (en) | Composition for treating osteoarthritis | |
| CN108865986A (en) | For repairing articular cartilage damage/defect mescenchymal stem cell preparation and its preparation method and application | |
| Zhu et al. | Transplantation of stem cells from human exfoliated deciduous teeth decreases cognitive impairment from chronic cerebral ischemia by reducing neuronal apoptosis in rats | |
| Wu et al. | Adipose-derived mesenchymal stem cells from a hypoxic culture improve neuronal differentiation and nerve repair | |
| Shao et al. | Wogonin inhibits inflammation and apoptosis through STAT3 signal pathway to promote the recovery of spinal cord injury | |
| CN106062184B (en) | The purposes of Odontogenic cysts stem cell and the Odontogenic cysts stem cell of gene modification | |
| CN107551095B (en) | A skin repairing agent for psoriasis prepared from stem cell extract and Chinese medicinal extract | |
| JP2017093431A (en) | Mesenchymal stem cells derived from fat, culture method of mesenchymal stem cells derived from fat, and therapeutic drug | |
| CN106701669A (en) | Mesenchymal stem cell for clinical treatment as well as preparation method and application thereof | |
| ES2690253T3 (en) | Method to expand adult stem cells from whole blood | |
| CN110179827A (en) | The application of Odontogenic cysts mescenchymal stem cell | |
| CN109498659A (en) | Application of the sandworm zymolyte in preparation prevention and treatment osteoarthritis drugs or health care product | |
| WO2013187194A1 (en) | Pharmaceutical composition effective for treatment of bone diseases | |
| CN110772534A (en) | Application of multisystem differentiation sustained stress cells in preparation of anti-inflammatory drugs | |
| Irdam et al. | A systematic review of intracavernosal injection of mesenchymal stem cells for diabetic erectile dysfunction. | |
| JP7083141B2 (en) | Compositions and Their Use to Improve Muscle Loss or Weakness | |
| US20200155608A1 (en) | Therapeutic Treatments Via Intravenous Infusion Of Mesenchymal Stem Cells | |
| CN110787188A (en) | Application of mouse umbilical cord mesenchymal stem cells in protection of blood brain barrier function damage after skin scald | |
| ES2862248T3 (en) | Use of allogeneic cells from the interstitial vascular layer and allogeneic mesenchymal progenitor cells to prevent or treat osteoarthritis | |
| CN104706675A (en) | Composition for treating osteoarthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB03 | Change of inventor or designer information | ||
| CB03 | Change of inventor or designer information |
Inventor after: Yang Yuefeng Inventor after: Zhu Xiaona Inventor after: Xia Xia Inventor after: Meng Hongfang Inventor after: Liu Hongying Inventor after: Liu Dongmei Inventor before: Yang Yuefeng Inventor before: Wu Zuze Inventor before: Zhu Xiaona Inventor before: Xia Xia Inventor before: Wang Hua Inventor before: Meng Hongfang Inventor before: Liu Hongying Inventor before: Liu Dongmei |
|
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190830 |